These results demonstrate that TGF-β is at least partly responsible for EGFR inhibitor-mediated tumor immune evasion, and that targeting the TGF-β pathway and/or COX-2 pathway might be powerful strategies for restoration of immunosuppression caused by blockade of EGFR. This evidence concerns the gene EGFR and neoplasm.